JP4383851B2 - 多糖類生体材料及びその使用 - Google Patents
多糖類生体材料及びその使用 Download PDFInfo
- Publication number
- JP4383851B2 JP4383851B2 JP2003506947A JP2003506947A JP4383851B2 JP 4383851 B2 JP4383851 B2 JP 4383851B2 JP 2003506947 A JP2003506947 A JP 2003506947A JP 2003506947 A JP2003506947 A JP 2003506947A JP 4383851 B2 JP4383851 B2 JP 4383851B2
- Authority
- JP
- Japan
- Prior art keywords
- heparin
- monomer
- group
- hydrogel
- macromer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920001282 polysaccharide Polymers 0.000 title description 112
- 239000005017 polysaccharide Substances 0.000 title description 112
- 239000012620 biological material Substances 0.000 title description 10
- 150000004676 glycans Chemical class 0.000 title 1
- 229920000669 heparin Polymers 0.000 claims description 177
- 229960002897 heparin Drugs 0.000 claims description 176
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 175
- 239000000017 hydrogel Substances 0.000 claims description 166
- 229920000642 polymer Polymers 0.000 claims description 126
- 239000000178 monomer Substances 0.000 claims description 110
- 238000000034 method Methods 0.000 claims description 60
- 239000003960 organic solvent Substances 0.000 claims description 45
- 210000004204 blood vessel Anatomy 0.000 claims description 32
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate group Chemical group C(C(=C)C)(=O)[O-] CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 25
- -1 methacryloxy Chemical group 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 22
- 229920002635 polyurethane Polymers 0.000 claims description 21
- 239000004814 polyurethane Substances 0.000 claims description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 20
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 17
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 17
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 17
- 238000009835 boiling Methods 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 16
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 15
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical group CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 12
- 229920000728 polyester Polymers 0.000 claims description 12
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 239000002473 artificial blood Substances 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 230000000379 polymerizing effect Effects 0.000 claims description 11
- 229920003023 plastic Polymers 0.000 claims description 10
- 239000004033 plastic Substances 0.000 claims description 10
- 238000004132 cross linking Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000001033 ether group Chemical group 0.000 claims description 7
- 239000004743 Polypropylene Substances 0.000 claims description 6
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229920001155 polypropylene Polymers 0.000 claims description 6
- 239000012948 isocyanate Substances 0.000 claims description 5
- 150000002513 isocyanates Chemical class 0.000 claims description 5
- 229920001451 polypropylene glycol Polymers 0.000 claims description 5
- 229920001296 polysiloxane Polymers 0.000 claims description 5
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 4
- 229920002379 silicone rubber Polymers 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims description 4
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 3
- 239000011247 coating layer Substances 0.000 claims description 3
- NEBBLNDVSSWJLL-UHFFFAOYSA-N 2,3-bis(2-methylprop-2-enoyloxy)propyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(OC(=O)C(C)=C)COC(=O)C(C)=C NEBBLNDVSSWJLL-UHFFFAOYSA-N 0.000 claims description 2
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 claims description 2
- UKMBKKFLJMFCSA-UHFFFAOYSA-N [3-hydroxy-2-(2-methylprop-2-enoyloxy)propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(CO)OC(=O)C(C)=C UKMBKKFLJMFCSA-UHFFFAOYSA-N 0.000 claims description 2
- WFYUNCXOGJSZPD-UHFFFAOYSA-N diazanium ethyl 2-methylprop-2-enoate sulfate Chemical compound C(C(=C)C)(=O)OCC.S(=O)(=O)([O-])[O-].[NH4+].[NH4+] WFYUNCXOGJSZPD-UHFFFAOYSA-N 0.000 claims description 2
- NLVXSWCKKBEXTG-UHFFFAOYSA-M ethenesulfonate Chemical compound [O-]S(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-M 0.000 claims description 2
- 229920005570 flexible polymer Polymers 0.000 claims description 2
- 239000004945 silicone rubber Substances 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 239000002861 polymer material Substances 0.000 claims 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 125000002130 sulfonic acid ester group Chemical group 0.000 claims 1
- SVTUWEUXLNHYPF-UHFFFAOYSA-N trimethyl-[propyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound CCC[Si](O[Si](C)(C)C)(O[Si](C)(C)C)O[Si](C)(C)C SVTUWEUXLNHYPF-UHFFFAOYSA-N 0.000 claims 1
- XOYXELNNPALJIE-UHFFFAOYSA-N trimethylazanium phosphate Chemical compound C[NH+](C)C.C[NH+](C)C.C[NH+](C)C.[O-]P([O-])([O-])=O XOYXELNNPALJIE-UHFFFAOYSA-N 0.000 claims 1
- 150000004804 polysaccharides Chemical class 0.000 description 111
- 239000000463 material Substances 0.000 description 69
- 239000000243 solution Substances 0.000 description 59
- 238000000576 coating method Methods 0.000 description 54
- 239000004744 fabric Substances 0.000 description 53
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 238000006243 chemical reaction Methods 0.000 description 45
- 239000011248 coating agent Substances 0.000 description 43
- 230000002792 vascular Effects 0.000 description 40
- 239000008280 blood Substances 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 238000006116 polymerization reaction Methods 0.000 description 29
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 26
- 239000000203 mixture Substances 0.000 description 23
- 229920002994 synthetic fiber Polymers 0.000 description 22
- 229920002683 Glycosaminoglycan Polymers 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 239000008367 deionised water Substances 0.000 description 15
- 229910021641 deionized water Inorganic materials 0.000 description 15
- 239000007943 implant Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 210000001367 artery Anatomy 0.000 description 13
- 230000017531 blood circulation Effects 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000011148 porous material Substances 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000010410 layer Substances 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 230000023555 blood coagulation Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- VHRYZQNGTZXDNX-UHFFFAOYSA-N methacryloyl chloride Chemical compound CC(=C)C(Cl)=O VHRYZQNGTZXDNX-UHFFFAOYSA-N 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000008467 tissue growth Effects 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 208000031481 Pathologic Constriction Diseases 0.000 description 6
- 239000008393 encapsulating agent Substances 0.000 description 6
- 230000036262 stenosis Effects 0.000 description 6
- 208000037804 stenosis Diseases 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 230000001453 nonthrombogenic effect Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000010526 radical polymerization reaction Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 229950003937 tolonium Drugs 0.000 description 5
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 5
- 206010002329 Aneurysm Diseases 0.000 description 4
- 102000004411 Antithrombin III Human genes 0.000 description 4
- 108090000935 Antithrombin III Proteins 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- 102000016611 Proteoglycans Human genes 0.000 description 4
- 108010067787 Proteoglycans Proteins 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000012644 addition polymerization Methods 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000002965 anti-thrombogenic effect Effects 0.000 description 4
- 229960005348 antithrombin iii Drugs 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- IIQWTZQWBGDRQG-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate;isocyanic acid Chemical compound N=C=O.CCOC(=O)C(C)=C IIQWTZQWBGDRQG-UHFFFAOYSA-N 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000012643 polycondensation polymerization Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 3
- 208000005422 Foreign-Body reaction Diseases 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000012412 chemical coupling Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002118 epoxides Chemical group 0.000 description 3
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- WYGWHHGCAGTUCH-UHFFFAOYSA-N 2-[(2-cyano-4-methylpentan-2-yl)diazenyl]-2,4-dimethylpentanenitrile Chemical compound CC(C)CC(C)(C#N)N=NC(C)(C#N)CC(C)C WYGWHHGCAGTUCH-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000011243 crosslinked material Substances 0.000 description 2
- 125000005442 diisocyanate group Chemical group 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- RBQRWNWVPQDTJJ-UHFFFAOYSA-N methacryloyloxyethyl isocyanate Chemical compound CC(=C)C(=O)OCCN=C=O RBQRWNWVPQDTJJ-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000006552 photochemical reaction Methods 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003752 saphenous vein Anatomy 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000006557 surface reaction Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000002885 thrombogenetic effect Effects 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N 1,4-butanediol Substances OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical group N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- BTFPHODXQGLBMA-UHFFFAOYSA-N 2-methylprop-2-enoic acid;urea Chemical compound NC(N)=O.CC(=C)C(O)=O BTFPHODXQGLBMA-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BESKSSIEODQWBP-UHFFFAOYSA-N 3-tris(trimethylsilyloxy)silylpropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC[Si](O[Si](C)(C)C)(O[Si](C)(C)C)O[Si](C)(C)C BESKSSIEODQWBP-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 206010060874 Aortic rupture Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000004964 aerogel Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- FWLORMQUOWCQPO-UHFFFAOYSA-N benzyl-dimethyl-octadecylazanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 FWLORMQUOWCQPO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000109 continuous material Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 239000012975 dibutyltin dilaurate Substances 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000004728 ear cartilage Anatomy 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- MHCLJIVVJQQNKQ-UHFFFAOYSA-N ethyl carbamate;2-methylprop-2-enoic acid Chemical compound CCOC(N)=O.CC(=C)C(O)=O MHCLJIVVJQQNKQ-UHFFFAOYSA-N 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000005496 phosphonium group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001042 thoracic artery Anatomy 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0064—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04B—KNITTING
- D04B21/00—Warp knitting processes for the production of fabrics or articles not dependent on the use of particular machines; Fabrics or articles defined by such processes
- D04B21/20—Warp knitting processes for the production of fabrics or articles not dependent on the use of particular machines; Fabrics or articles defined by such processes specially adapted for knitting articles of particular configuration
- D04B21/205—Elongated tubular articles of small diameter, e.g. coverings or reinforcements for cables or hoses
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2403/00—Details of fabric structure established in the fabric forming process
- D10B2403/01—Surface features
- D10B2403/012—Alike front and back faces
- D10B2403/0122—Smooth surfaces, e.g. laminated or coated
-
- D—TEXTILES; PAPER
- D10—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B—INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
- D10B2509/00—Medical; Hygiene
- D10B2509/06—Vascular grafts; stents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Textile Engineering (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30117601P | 2001-06-26 | 2001-06-26 | |
| PCT/GB2002/002940 WO2003000305A2 (en) | 2001-06-26 | 2002-06-26 | Polysaccharide biomaterials and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534579A JP2004534579A (ja) | 2004-11-18 |
| JP2004534579A5 JP2004534579A5 (enExample) | 2006-01-05 |
| JP4383851B2 true JP4383851B2 (ja) | 2009-12-16 |
Family
ID=23162274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003506947A Expired - Fee Related JP4383851B2 (ja) | 2001-06-26 | 2002-06-26 | 多糖類生体材料及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8101196B2 (enExample) |
| EP (1) | EP1401511A2 (enExample) |
| JP (1) | JP4383851B2 (enExample) |
| AU (1) | AU2002350289B2 (enExample) |
| CA (1) | CA2451255C (enExample) |
| WO (1) | WO2003000305A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101196B2 (en) * | 2001-06-26 | 2012-01-24 | Biointeractions, Ltd. | Polysaccharide biomaterials and methods of use thereof |
| US7655038B2 (en) * | 2003-02-28 | 2010-02-02 | Biointeractions Ltd. | Polymeric network system for medical devices and methods of use |
| US7978716B2 (en) * | 2003-11-24 | 2011-07-12 | Citrix Systems, Inc. | Systems and methods for providing a VPN solution |
| JP4566189B2 (ja) * | 2004-03-15 | 2010-10-20 | テルモ株式会社 | 癒着防止材 |
| US20050208093A1 (en) | 2004-03-22 | 2005-09-22 | Thierry Glauser | Phosphoryl choline coating compositions |
| US9561309B2 (en) | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
| US20060095121A1 (en) * | 2004-10-28 | 2006-05-04 | Medtronic Vascular, Inc. | Autologous platelet gel on a stent graft |
| US9297928B2 (en) | 2004-11-22 | 2016-03-29 | Johnson & Johnson Vision Care, Inc. | Ophthalmic compositions comprising polyether substituted polymers |
| US8431226B2 (en) * | 2005-03-30 | 2013-04-30 | Biomet Manufacturing Corp. | Coated medical device |
| US11896505B2 (en) | 2005-10-31 | 2024-02-13 | Scott M. Epstein | Methods for making and using a structural hydrogel polymer device |
| US8048350B2 (en) * | 2005-10-31 | 2011-11-01 | Scott Epstein | Structural hydrogel polymer device |
| US8052714B2 (en) | 2005-11-22 | 2011-11-08 | Medtronic Vascular, Inc. | Radiopaque fibers and filtration matrices |
| JP2010511415A (ja) * | 2005-12-01 | 2010-04-15 | イノグラフト,リミティド ライアビリティー カンパニー | 薄皮膜の施用のためにポリサッカライド物質をイオン架橋する方法及びそれから生成された製品 |
| US20070160743A1 (en) * | 2006-01-09 | 2007-07-12 | Babitt John L | Method for coating biocompatible material on a substrate |
| JP2010500917A (ja) | 2006-06-15 | 2010-01-14 | マイクロベンション, インコーポレイテッド | 膨張性ポリマーで構成される塞栓形成デバイス |
| US8685430B1 (en) | 2006-07-14 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Tailored aliphatic polyesters for stent coatings |
| US10188826B2 (en) * | 2006-09-29 | 2019-01-29 | Covidien Lp | Catheters including antimicrobial sleeve and methods of making catheters |
| US20080114096A1 (en) * | 2006-11-09 | 2008-05-15 | Hydromer, Inc. | Lubricious biopolymeric network compositions and methods of making same |
| CA2783363A1 (en) * | 2007-03-15 | 2008-09-18 | The Polymer Technology Group Incorporated | Functionalized polyvinylpyrrolidone |
| JP2010529047A (ja) * | 2007-06-08 | 2010-08-26 | クィーンズランド ユニバーシティ オブ テクノロジー | 創傷修復組成物および方法 |
| US20090136553A1 (en) * | 2007-09-25 | 2009-05-28 | Gerlach Jorg C | Triggerably dissolvable hollow fibers for controlled delivery |
| BRPI0821070B1 (pt) | 2007-12-21 | 2018-10-23 | Microvention Inc | dispositivo para implantação e método para a preparação de um filamento de hidrogel para implantação em um animal |
| EP2424775B1 (en) | 2009-04-30 | 2016-02-10 | Technip France | Spar mooring line sharing method and system |
| WO2011053555A1 (en) | 2009-10-26 | 2011-05-05 | Microvention, Inc. | Embolization device constructed from expansile polymer |
| US8448457B2 (en) * | 2009-11-23 | 2013-05-28 | Sartorius Stedim North America Inc. | Systems and methods for use in freezing, thawing, and storing biopharmaceutical materials |
| RU2012126318A (ru) * | 2009-11-27 | 2014-01-10 | Басф Се | Дендритная полимочевина для солюбилизации труднорастворимых действующих веществ |
| EP2384725B1 (de) * | 2010-05-06 | 2018-07-04 | Biotronik AG | Biokorrodierbares Implantat, bei dem eine Korrosion nach erfolgter Implantation durch einen externen Stimulus ausgelöst oder beschleunigt werden kann |
| US10751206B2 (en) | 2010-06-26 | 2020-08-25 | Scott M. Epstein | Catheter or stent delivery system |
| US20110319902A1 (en) | 2010-06-26 | 2011-12-29 | Scott Epstein | Catheter delivery system |
| US9456823B2 (en) | 2011-04-18 | 2016-10-04 | Terumo Corporation | Embolic devices |
| US9567357B2 (en) | 2011-06-24 | 2017-02-14 | Biointeractions Ltd. | Biocompatible, biomimetic ampholyte materials |
| DE102012008656A1 (de) * | 2011-12-29 | 2013-07-04 | Nonwotecc Medical Gmbh | Struktur mit stellenweise miteinander verklebten Fasern |
| WO2013158781A1 (en) | 2012-04-18 | 2013-10-24 | Microvention, Inc. | Embolic devices |
| EP3984556B8 (en) | 2012-06-14 | 2025-07-09 | Microvention, Inc. | Polymeric treatment compositions |
| US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
| CN104717983B (zh) | 2012-10-15 | 2018-09-18 | 微仙美国有限公司 | 聚合治疗组合物 |
| AU2014264335B2 (en) * | 2013-03-15 | 2017-05-11 | Valve Medical Ltd. | System and method for sealing percutaneous valve |
| USRE49528E1 (en) | 2013-04-26 | 2023-05-16 | Biointeractions Ltd. | Bioactive coatings |
| US10206945B2 (en) | 2013-04-26 | 2019-02-19 | Biointeractions Ltd. | Bioactive coatings |
| CN103272280A (zh) * | 2013-05-24 | 2013-09-04 | 南京大学医学院附属鼓楼医院 | 一种对脱细胞血管支架或人造血管改性的方法 |
| WO2015073758A1 (en) | 2013-11-15 | 2015-05-21 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
| US10124090B2 (en) | 2014-04-03 | 2018-11-13 | Terumo Corporation | Embolic devices |
| WO2015167752A1 (en) | 2014-04-29 | 2015-11-05 | Microvention, Inc. | Polymers including active agents |
| US10092663B2 (en) | 2014-04-29 | 2018-10-09 | Terumo Corporation | Polymers |
| CA2970010A1 (en) | 2014-12-09 | 2016-06-16 | Karen Havenstrite | Medical device coating with a biocompatible layer |
| WO2016201250A1 (en) | 2015-06-11 | 2016-12-15 | Microvention, Inc. | Expansile device for implantation |
| JP6310167B2 (ja) | 2016-01-14 | 2018-04-11 | 学校法人大阪医科薬科大学 | 経編地及び医療材料 |
| US9861410B2 (en) | 2016-05-06 | 2018-01-09 | Medos International Sarl | Methods, devices, and systems for blood flow |
| US10368874B2 (en) | 2016-08-26 | 2019-08-06 | Microvention, Inc. | Embolic compositions |
| CN111200976B (zh) | 2017-10-09 | 2023-07-07 | 微仙美国有限公司 | 放射性液体栓塞 |
| US11027046B2 (en) | 2017-10-31 | 2021-06-08 | Hothouse Medical Limited | Textile products having selectively applied sealant or coating and method of manufacture |
| JP2022528428A (ja) | 2019-03-19 | 2022-06-10 | ジェイメドテック・コーティング・テクノロジーズ・プライベイト・リミテッド | 共有結合したヘパリン・コーティングを備える医療デバイス |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3954583A (en) | 1972-05-30 | 1976-05-04 | The Upjohn Company | Photochemical process |
| JPS5250399A (en) * | 1975-10-21 | 1977-04-22 | Agency Of Ind Science & Technol | Process for preparing anticoagulating organosilicon polymers |
| US4239664A (en) * | 1978-10-31 | 1980-12-16 | Research Corporation | Anti-thrombogenic PVP-heparin polymer |
| US4469827A (en) * | 1978-12-15 | 1984-09-04 | Hospal-Sodip Sa | Mixtures of polymers for medical use |
| US4331697A (en) * | 1980-09-02 | 1982-05-25 | Teijin Limited | Novel heparin derivative, method for production thereof, and method for rendering biomedical materials antithrombotic by use of the novel heparin derivative |
| DE3038288C1 (de) | 1980-10-10 | 1982-04-08 | Robert Bürkle GmbH & Co, 7290 Freudenstadt | Vorrichtung zur Erfassung des Fliesspunktes von Harzlaminaten bei der Herstellung von Mehrschichtleiterplatten |
| SU1078894A1 (ru) | 1982-04-23 | 1998-01-10 | Московский государственный университет им.М.В.Ломоносова | Способ получения гемосовместимых полимерных гидрогелей |
| US4722906A (en) | 1982-09-29 | 1988-02-02 | Bio-Metric Systems, Inc. | Binding reagents and methods |
| US5512329A (en) * | 1982-09-29 | 1996-04-30 | Bsi Corporation | Substrate surface preparation |
| EP0149693B1 (en) | 1984-01-20 | 1988-06-29 | Dräger Nederland B.V. | Method of forming an antithrombogenic layer on medical devices |
| CH665954A5 (fr) * | 1985-07-08 | 1988-06-30 | Battelle Memorial Institute | Substrat dont la surface presente une activite antithrombogenique. |
| US5047020A (en) * | 1987-09-14 | 1991-09-10 | Baxter International Inc. | Ionic heparin coating |
| JP2855224B2 (ja) | 1988-07-22 | 1999-02-10 | バイオ―メトリック システムズ,アイエヌシー. | 高分子表面の調製 |
| US5270046A (en) * | 1988-09-27 | 1993-12-14 | Ube Industries, Ltd. | Heparin bound anti-thrombotic material |
| US5529914A (en) * | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
| US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| DE4034882A1 (de) * | 1990-11-02 | 1992-05-07 | Starchem Gmbh | Verfahren zur herstellung von feinteiligen, wasserquellbaren polysaccharid-pfropfpolymeren |
| CA2063478A1 (en) * | 1991-03-22 | 1992-09-23 | Michael F. Novits | Scorch extending curing/crosslinking compositions |
| CA2109960C (en) * | 1991-05-31 | 2000-07-18 | Li-Chien Hsu | Thromboresistant coating for defoaming applications |
| US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| US5510016A (en) * | 1991-08-15 | 1996-04-23 | Mobil Oil Corporation | Gasoline upgrading process |
| WO1993005825A1 (en) * | 1991-09-20 | 1993-04-01 | Baxter International Inc. | Processes for reducing the thrombogenicity of biomaterials |
| US5837747A (en) * | 1991-10-29 | 1998-11-17 | Vivorx, Inc. | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
| JP2855307B2 (ja) * | 1992-02-05 | 1999-02-10 | 生化学工業株式会社 | 光反応性グリコサミノグリカン、架橋グリコサミノグリカン及びそれらの製造方法 |
| NZ249770A (en) * | 1992-02-28 | 1996-09-25 | Univ Texas | Biodegradable, polymerisable, substantially water soluble macromer comprising at least one water soluble region, at least one degradable region and at least two free radical polymerisable regions separated by at least one degradable region |
| US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
| US5344455A (en) * | 1992-10-30 | 1994-09-06 | Medtronic, Inc. | Graft polymer articles having bioactive surfaces |
| EP0623150A4 (en) * | 1992-11-19 | 1999-08-25 | Univ Case Western Reserve | Nonthrombogenic implant surfaces. |
| US5864530A (en) | 1993-01-04 | 1999-01-26 | U.S. Philips Corporation | Multiplane information storage system and record carrier for use in such a system |
| US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
| US5531715A (en) * | 1993-05-12 | 1996-07-02 | Target Therapeutics, Inc. | Lubricious catheters |
| ITPD940054A1 (it) * | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
| US6015429A (en) * | 1994-09-08 | 2000-01-18 | Gore Enterprise Holdings, Inc. | Procedures for introducing stents and stent-grafts |
| US5583213A (en) * | 1995-05-12 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Process to activate sulfated polysaccharides |
| US5581588A (en) | 1995-06-23 | 1996-12-03 | General Electric Company | Insulated protective coating doped with a noble metal for mitigation of stress corrosion cracking |
| EP0769503A3 (en) | 1995-10-17 | 1997-10-08 | Terumo Corp | Heparin complex and medical device containing such compound |
| DE69632996T2 (de) * | 1995-12-26 | 2005-07-21 | Toyo Boseki K.K. | In organischen Lösungsmitteln lösliche Mucopolysaccharide, antibakterielles antithrombogenes Mittel und medizinisches Material |
| US5871537A (en) * | 1996-02-13 | 1999-02-16 | Scimed Life Systems, Inc. | Endovascular apparatus |
| GB9603146D0 (en) | 1996-02-15 | 1996-04-17 | Innovative Tech Ltd | Hydrogels |
| GB9608882D0 (en) * | 1996-04-30 | 1996-07-03 | Luthra Ajay K | Non-thrombogenic and anti-thrombogenic polymers |
| US6368356B1 (en) * | 1996-07-11 | 2002-04-09 | Scimed Life Systems, Inc. | Medical devices comprising hydrogel polymers having improved mechanical properties |
| US5854406A (en) * | 1996-07-11 | 1998-12-29 | Wako Pure Chemical Industries, Ltd. | High molecular weight azoamide compound |
| US5851229A (en) * | 1996-09-13 | 1998-12-22 | Meadox Medicals, Inc. | Bioresorbable sealants for porous vascular grafts |
| US5855618A (en) * | 1996-09-13 | 1999-01-05 | Meadox Medicals, Inc. | Polyurethanes grafted with polyethylene oxide chains containing covalently bonded heparin |
| US5741881A (en) * | 1996-11-25 | 1998-04-21 | Meadox Medicals, Inc. | Process for preparing covalently bound-heparin containing polyurethane-peo-heparin coating compositions |
| US5877263A (en) * | 1996-11-25 | 1999-03-02 | Meadox Medicals, Inc. | Process for preparing polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents |
| US5728751A (en) * | 1996-11-25 | 1998-03-17 | Meadox Medicals, Inc. | Bonding bio-active materials to substrate surfaces |
| US6121027A (en) | 1997-08-15 | 2000-09-19 | Surmodics, Inc. | Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups |
| US5945457A (en) * | 1997-10-01 | 1999-08-31 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science | Process for preparing biologically compatible polymers and their use in medical devices |
| US5975457A (en) * | 1998-03-09 | 1999-11-02 | Forbes; Thomas J. | Web feeding systems |
| US6007833A (en) * | 1998-03-19 | 1999-12-28 | Surmodics, Inc. | Crosslinkable macromers bearing initiator groups |
| US6248127B1 (en) * | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
| JP2002523476A (ja) | 1998-08-27 | 2002-07-30 | エイドゲントシッシュ テクニーシェ ホッシュール チューリッヒ | ボロン酸含有ポリマー由来のゲルおよび多層表面構造 |
| US6299980B1 (en) * | 1998-09-29 | 2001-10-09 | Medtronic Ave, Inc. | One step lubricious coating |
| US6258121B1 (en) * | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
| US6358557B1 (en) * | 1999-09-10 | 2002-03-19 | Sts Biopolymers, Inc. | Graft polymerization of substrate surfaces |
| WO2001068722A1 (en) * | 2000-03-13 | 2001-09-20 | Biocure, Inc. | Hydrogel biomedical articles |
| US6630460B2 (en) * | 2001-02-09 | 2003-10-07 | Medtronic, Inc. | Heparin compositions and methods of making and using the same |
| US8101196B2 (en) * | 2001-06-26 | 2012-01-24 | Biointeractions, Ltd. | Polysaccharide biomaterials and methods of use thereof |
| JP4759858B2 (ja) * | 2001-07-04 | 2011-08-31 | 和光純薬工業株式会社 | 粉末アゾ化合物 |
-
2002
- 2002-06-25 US US10/179,453 patent/US8101196B2/en not_active Expired - Lifetime
- 2002-06-26 CA CA2451255A patent/CA2451255C/en not_active Expired - Fee Related
- 2002-06-26 EP EP02751298A patent/EP1401511A2/en not_active Withdrawn
- 2002-06-26 WO PCT/GB2002/002940 patent/WO2003000305A2/en not_active Ceased
- 2002-06-26 JP JP2003506947A patent/JP4383851B2/ja not_active Expired - Fee Related
- 2002-06-26 AU AU2002350289A patent/AU2002350289B2/en not_active Ceased
-
2004
- 2004-01-05 US US10/751,706 patent/US20040142016A1/en not_active Abandoned
-
2011
- 2011-07-15 US US13/183,922 patent/US9127091B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2451255A1 (en) | 2003-01-03 |
| US8101196B2 (en) | 2012-01-24 |
| CA2451255C (en) | 2012-11-27 |
| WO2003000305A2 (en) | 2003-01-03 |
| US20030021762A1 (en) | 2003-01-30 |
| AU2002350289B2 (en) | 2008-03-13 |
| US20110274821A1 (en) | 2011-11-10 |
| US9127091B2 (en) | 2015-09-08 |
| WO2003000305A3 (en) | 2003-04-17 |
| EP1401511A2 (en) | 2004-03-31 |
| JP2004534579A (ja) | 2004-11-18 |
| US20040142016A1 (en) | 2004-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4383851B2 (ja) | 多糖類生体材料及びその使用 | |
| Ratner et al. | Synthetic hydrogels for biomedical applications | |
| JP2992556B2 (ja) | 表面改質した医療器具 | |
| US6231605B1 (en) | Poly(vinyl alcohol) hydrogel | |
| US5851229A (en) | Bioresorbable sealants for porous vascular grafts | |
| EP0397130B1 (en) | Medical device having highly biocompatible surface and method for manufacturing the same | |
| US20030008396A1 (en) | Poly(vinyl alcohol) hydrogel | |
| AU2013232382A1 (en) | Glycosaminoglycan and synthetic polymer materials for blood-contacting applications | |
| ES3041780T3 (en) | Orthopaedic cement removal tools | |
| WO1992009312A1 (en) | Implant material | |
| JP2018099543A (ja) | 固定された生物学的実体 | |
| Ai et al. | Gelatin-glutaraldehyde cross-linking on silicone rubber to increase endothelial cell adhesion and growth | |
| WO2008067518A2 (en) | Methods for ionically cross-linking gellan gum for thin film applications and medical devices produced therefrom | |
| WO1996008149A9 (en) | Thromboresistant surface treatment for biomaterials | |
| KR20120087049A (ko) | 친수성기가 도입된 인공혈관 | |
| Aleyamma et al. | Polyvinyl alcohol as a biomaterial | |
| Wilson | Hemocompatible polymers: preparation and properties | |
| JPS61263448A (ja) | 血管補綴物 | |
| JPH0240341B2 (enExample) | ||
| JPS60190966A (ja) | 抗血栓性材料 | |
| JPH03103264A (ja) | 生体適合性に優れた表面を有する医療用具の製造方法 | |
| JPH09103481A (ja) | 生体適合性に優れた表面を有する医療用具およびその製造方法 | |
| Dumitriu et al. | Polymeric Biomaterials As Enzyme and Drug Carriers* Part V: Polymeric Matrices as Drug Delivery Systems | |
| Leininger | 4.2 POLYMERS AS SURGICAL IMPLANTS | |
| Pitt | United States Patent po |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050627 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050627 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090227 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090527 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090603 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090625 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090724 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090821 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090924 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121002 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131002 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |